Both in Biotechnology
TScan Therapeutics vs Intensity Therapeutics
Over the past year TCRX returned −81.3% and INTS returned −73.8%; their daily moves had a correlation of 0.13.
TCRX −81.3% INTS −73.8%Growth of $1, one year, split-adjusted
| Metric | TCRX | INTS |
|---|---|---|
| Price | $0.2100 | $3.50 |
| Market cap | $14.2M | $11.4M |
| Today | +11.11% | +3.55% |
| 1 month | −23.7% | −1.4% |
| 6 months | −83.2% | −32.8% |
| Year to date | −79.0% | −65.9% |
| 1 year | −83.1% | −77.4% |
| Revenue growth (YoY) | −65.8% | — |
| Gross margin | 100.0% | — |
| Net margin | −2888.6% | — |
| P/E (TTM) | — | — |
| Price / sales | 2.0× | — |
| Net cash | $67.4M | $9.5M |
| Dividend yield | — | — |
| Volatility (60d) | 143.0% | 62.6% |
| Short % of float | 4.1% | 2.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).